{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T20:13:01Z","timestamp":1772223181181,"version":"3.50.1"},"reference-count":9,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p>A 63\u2010year\u2010old man with hepatocellular carcinoma consequent to chronic viral hepatitis C presented with severe dermatitis on the lower right side of the back after transcatheter arterial chemoembolization (TACE) via the 10th intercostal artery, because his hepatic artery had already collapsed due to repeated usage for TACE. The regional skin showed redness and hardness with pustules. Histologically, there was epidermal and appendage necrosis, as well as exocytosis of red blood cells. With a diagnosis of skin injury due to leakage of lipiodol ultrafluid, mitomycin, and epirubicin, administered via the 10th intercostal artery, onto the skin tissue, topical application of 0.06% fluocinonide\u2010containing cream was prescribed.<\/jats:p><jats:p>After several weeks of conservative local treatment, the leakage skin injury improved significantly, leaving pigmentation, hardness, and a small necrotic mass, as reported elsewhere (Honda T, Matsushima S, Fujii S, <jats:italic>et\u00a0al.<\/jats:italic> A case of skin injury following transcatheter arterial chemotherapy through intercostal artery for hepatocellular carcinoma. <jats:italic>Skin Res<\/jats:italic> 2003; <jats:bold>2:<\/jats:bold> 18\u201322).<\/jats:p><jats:p>Subsequently, the patient again consulted the Dermatology Department with further dermatitis in an almost identical skin region on the right side of the abdomen (irregularly spreading erythematous and edematous eruptions with itching; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#f1\">Fig.\u00a01<\/jats:ext-link>). As he had undergone an ultrasonic examination 2\u00a0days earlier, allergic contact dermatitis from the ultrasonic gel was suspected. The contact dermatitis was treated with a topical corticosteroid hormone\u2010containing ointment. Patch testing was performed with Ultra Phonic Conductivity Gel (Pharmaceutical Innovations Inc., Newark, NJ, USA), with which the patient had undergone a series of ultrasonic examinations, and Sono Jelly (Toshiba Medical Supply Co., Ltd., Tokyo, Japan) as a reference, as well as white petroleum as a negative control. A positive result was obtained for Ultra Phonic Conductivity Gel, whereas Sono Jelly was negative (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#f2\">Fig.\u00a02a<\/jats:ext-link>).<\/jats:p><jats:p><jats:fig><jats:caption><jats:p>(A) The dorsal aspect of the right side of the lower back shows irregularly shaped erythema on the previous anticancer drug leakage dermatitis with a remaining ulcer. (B) The frontal aspect of the lower right abdomen shows urtico\u2010erythematous eruptions indicating contact dermatitis after ultrasonic examination of the liver<\/jats:p><\/jats:caption><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" position=\"anchor\" xlink:href=\"urn:x-wiley:00119059:media:IJD2207:IJD_2207_f1\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:fig><\/jats:p><jats:p><jats:fig><jats:caption><jats:p>(A) A patch test with Ultra Phonic Conductivity Gel (UPCG), with which the patient underwent repeated ultrasonic examinations, was positive. Sono Jelly (SJ) as a reference was negative, as was white petroleum as a negative control (NC). (B) Patch tests with PG (1), preservative in PG (2), and color in PG (3) were positive, but thickener 1 (4), thickener 2 (5), and lipiodol ultrafluid (6) were negative, as was the negative control (7). (C) Patch tests with commercially obtained PG series were as follows: original (2), strongly positive; 10% (3), positive; 1% (4) and 0.1% (5), weakly positive; all compared with the negative control (1)<\/jats:p><\/jats:caption><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" position=\"anchor\" xlink:href=\"urn:x-wiley:00119059:media:IJD2207:IJD_2207_f2\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:fig><\/jats:p><jats:p>Pharmaceutical Innovations Inc. kindly supplied the ingredients of the gel: propylene glycol (PG), preservative in PG, color in PG, thickener 1, and thickener 2. The company gave no further details about the preservative, color, and thickeners. Patch testing was performed using these five materials, resulting in a positive reaction for PG, preservative in PG, and color in PG. Thickeners 1 and 2 and lipiodol ultrafluid were negative (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#f2\">Fig.\u00a02b<\/jats:ext-link>). On the assumption that the causative chemical was PG, commercially obtained PG, free of preservative and color, was then patch tested (original, 10% aqueous, 1% aqueous, and 0.1% aqueous solutions), resulting in original strongly positive, 10% positive, and 1% and 0.1% weakly positive (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#f2\">Fig.\u00a02c<\/jats:ext-link>).<\/jats:p><jats:p>The medical records showed that the patient had received 16 ultrasonic examinations with the same ultrasonic gel before the leakage skin injury. The 17th examination was performed 2\u00a0days after leakage dermatitis, and the 18th 3\u00a0months after the injury, when contact dermatitis occurred. The 19th examination was performed using Sono Jelly, which contains no PG, and no skin problems were observed.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2004.02207.x","type":"journal-article","created":{"date-parts":[[2005,8,3]],"date-time":"2005-08-03T16:10:53Z","timestamp":1123085453000},"page":"681-683","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A case of allergic contact dermatitis from propylene glycol in an ultrasonic gel, sensitized at a leakage skin injury due to transcatheter arterial chemoembolization for hepatocellular carcinoma"],"prefix":"10.1111","volume":"44","author":[{"given":"Yuji","family":"Horiguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7,20]]},"reference":[{"key":"e_1_2_2_2_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1034\/j.1600-0536.2001.440107-6.x","article-title":"Allergic contact dermatitis due to methyldibromo glutaronitrile in Euxyl K 400 in an ultrasonic gel","volume":"44","author":"Erdmann SM","year":"2001","journal-title":"Contact Dermatitis"},{"key":"e_1_2_2_3_2","first-page":"109","article-title":"Allergic contact dermatitis from imidazolidinyl urea in an ultrasonic gel","volume":"42","author":"Ando M","year":"2000","journal-title":"Contact Dermatitis"},{"key":"e_1_2_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1993.tb03564.x"},{"key":"e_1_2_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1987.tb02681.x"},{"key":"e_1_2_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02190.x"},{"key":"e_1_2_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1994.tb01995.x"},{"key":"e_1_2_2_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.119104"},{"key":"e_1_2_2_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajcd.2001.29550"},{"key":"e_1_2_2_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2002.00997.x"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2004.02207.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2004.02207.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T08:36:02Z","timestamp":1696926962000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2004.02207.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,20]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1365-4632.2004.02207.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02207.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,20]]},"assertion":[{"value":"2005-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}